ESTRO 2021 Abstract Book

S762

ESTRO 2021

<50yrs (Pearson’s Chi-Square p<0.01). If respondents would now face a treatment decision, 88% (n=654) (29% likely and 59% very likely) would likely use a decision aid to gain insight into the side effects of treatment. A digital decision aid (71%; n=525) was preferred over a paper version (11%; n=80), of which 72% (n=380) preferring the option to print results. 89% (n=662) of the women indicated that they wanted to know their personal risk on a certain side effect before starting treatment, with 64% indicating the need to explain the implications by the physician and 52% indicating to want to know the impact on daily life.

Conclusion Having enough energy is by far the most important quality of life theme for women with breast cancer, reinforcing the need for fatigue research. Half of the women that received radiation therapy had not discussed the advantages and disadvantages with their physician before treatment. Half of the women has never heard of a decision aid but the large majority would use it if they would face a treatment decision. Although women would like to know their personal risk on a side effect, two-third would like additional information from the physician with regard to the implications and impact. PD-0921 Long-term quality of life of surviving elderly head-and-neck cancer patients after (chemo)radiation A. Rühle 1 , E. Haehl 1 , T. Kalckreuth 1 , R. Stoian 1 , T. Sprave 1 , C. Zamboglou 1 , E. Gkika 1 , A. Knopf 2 , A. Grosu 1 , N. Nicolay 1 1 University Medical Center Freiburg, Department of Radiation Oncology, Freiburg, Germany; 2 University Medical Center Freiburg, Department of Otorhinolaryngology, Freiburg, Germany Purpose or Objective Considering the challenge to choose the optimal treatment for elderly head-and-neck squamous cell carcinoma (HNSCC) patients, there is a need to have profound data about the long-term impact of (chemo)radiation on the health-related quality of life (QoL) of this vulnerable patient cohort. However, the majority of QoL studies included HNSCC patients irrespectively of their age and did not particularly focus on the QoL of elderly patients. Materials and Methods Patient-reported QoL was examined within a cross-sectional study at a tertiary cancer center. HNSCC patients aged ≥65 years at the time of radiotherapy and alive for ≥1 year after radiotherapy were eligible for the analysis. The EORTC QLQ-C30 and QLQ-H&N35 were used for QoL assessment, while the ZUF-8 was used for patient satisfaction evaluation. Results 284 patients receiving curative chemoradiation between 2008 and 2019 were screened, of which 74 patients were still alive and not lost to follow-up. Of these patients, 50 patients agreed to participate into the study. The median age ranged at 69 years (range 65-82) at the time of radiotherapy, and the median interval between radiation and QoL assessment amounted to 32 months (range 12-113). Median Karnofsky Performance Status and Charlson Comorbidity Index were 90% (range 60-100%) and 3 points (range 2-10), respectively. The global QoL was in median 66.7 points (interquartile range [IQR] 50.0-83.3) which was comparable with the age- and gender-matched German population (65.3). There was no difference regarding the global QoL between definitive (median 75.0, IQR 50.0-83.3) and adjuvant chemoradiation (median 66.7, IQR 41.7-83.3) ( p =0.219, Mann-Whitney-U test). While patients in the definitive (chemo)radiation group reported about less troubles with social eating ( p <0.05) and mouth opening ( p <0.01), patients in the adjuvant (chemo)radiation group showed less problems regarding sexuality ( p <0.01). Elderly HPV-positive HNSCC patients exhibited a significantly better QoL than elderly HPV-negative patients ( p <0.05). There was no difference regarding the global QoL between patients undergoing radiation alone and patients receiving chemoradiation ( p =0.966). Global QoL was independent from physician-assessed chronic toxicities ( p =0.640, Kruskal-Wallis test). Patient satisfaction of the cohort was relatively good, shown by a median ZUF-8 score of 29 out of 32 points (IQR 27- 31). Conclusion Surviving elderly HNSCC patients exhibit a similar health-related QoL after (chemo)radiation compared to the